Oncoinvent ASA (ONCIN.OL)
Oslo · NOK · Healthcare · Biotechnology
NOK 68.20 (+0.00%) as of
Key statistics
- Market cap
- 417.96M
- Forward P/E
- -3.01
- EPS (TTM)
- -83.20
- Dividend yield
- 0.00%
- 52-week range
- 40.10 – 144.00
- Revenue (TTM)
- 24.31M
- Profit margin
- 0.00%
- Analyst target
- NOK 110.00
- Volume
- 20.86k
About Oncoinvent ASA
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Oslo, Norway
- Employees
- 42
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.